BCR+ and BCR− patients were identified and selected from a retrospective group of prostate cancer patients who had previously undergone definitive therapy and for whom the outcomes had been recorded, all under the auspices of an IRB approved study. This evidence concerns the gene BCR and prostate carcinoma.